CHN NATL. MED. CORP. sees an upgrade to Slightly Positive due to a better fundamental star rating
The general evaluation of CHN NATL. MED. CORP. (CN), a company active in the Drug Retailers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 22, 2022, the closing price was CNY 27.87 and its potential was estimated at CNY 32.31.China National Medicines is engaged in the distribution of Chinese patent drugs, chemical drug, antibiotic, biomedicine, biological products, narcotic, first and second class of psychoactive drug and vaccine (valid till Jan 30 2010); sale of health care products (valid till Apr 12 2010); production of medicine; import and export business; provision of advisory services with regard to the above businesses; sale of II and III class of medical machine (valid till Nov 16 2011) and packaged food. Through its subsidiaries, Co. is also engaged in the provision of warehousing, logistic and information services.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.